Premium
Inclusive Biomedical Innovation during the COVID‐19 Pandemic
Author(s) -
Pannu Jaspreet
Publication year - 2020
Publication title -
global policy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.602
H-Index - 33
eISSN - 1758-5899
pISSN - 1758-5880
DOI - 10.1111/1758-5899.12876
Subject(s) - covid-19 , pandemic , dual (grammatical number) , malaria , development economics , economics , business , political science , economic growth , law and economics , biology , virology , medicine , infectious disease (medical specialty) , immunology , art , literature , disease , pathology , outbreak
CEPI represents the first step towards Joseph Stiglitz’s vision, cited by Gubby, of a fund which provides large rewards for cures to common diseases such as malaria, and smaller rewards for rarer diseases or less innovative ‘me‐too’ drugs (Stiglitz, BMJ , 333, 2006, pp. 1279–1280). As a fledgling organization facing a Goliath, it deserves international support in its dual goals of incentivizing innovation and ensuring equitable access to biomedical advances.